Hyperfine, Inc. (HYPR): Price and Financial Metrics
HYPR Price/Volume Stats
Current price | $1.19 | 52-week high | $3.28 |
Prev. close | $1.18 | 52-week low | $0.91 |
Day low | $1.18 | Volume | 67,900 |
Day high | $1.26 | Avg. volume | 58,353 |
50-day MA | $1.07 | Dividend yield | N/A |
200-day MA | $1.66 | Market Cap | 85.20M |
HYPR Stock Price Chart Interactive Chart >
HYPR POWR Grades
- Sentiment is the dimension where HYPR ranks best; there it ranks ahead of 91.48% of US stocks.
- The strongest trend for HYPR is in Growth, which has been heading down over the past 26 weeks.
- HYPR ranks lowest in Quality; there it ranks in the 2nd percentile.
HYPR Stock Summary
- For HYPR, its debt to operating expenses ratio is greater than that reported by just 0.22% of US equities we're observing.
- HYPR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.84% of US stocks.
- As for revenue growth, note that HYPR's revenue has grown 67.7% over the past 12 months; that beats the revenue growth of 93.32% of US companies in our set.
- Stocks that are quantitatively similar to HYPR, based on their financial statements, market capitalization, and price volatility, are GPRO, SCKT, HCWB, PDEX, and KOPN.
- To dig deeper into the stock's financial statements, go to HYPR's page on browse-edgar?action=getcompany&CIK=0001833769.
HYPR Valuation Summary
- In comparison to the median Healthcare stock, HYPR's price/sales ratio is 272.73% higher, now standing at 8.2.
- HYPR's EV/EBIT ratio has moved up 8.3 over the prior 36 months.
Below are key valuation metrics over time for HYPR.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
HYPR | 2023-12-29 | 8.2 | 0.9 | -1.7 | 0.1 |
HYPR | 2023-12-28 | 8.0 | 0.8 | -1.7 | 0.2 |
HYPR | 2023-12-27 | 7.8 | 0.8 | -1.6 | 0.2 |
HYPR | 2023-12-26 | 7.5 | 0.8 | -1.6 | 0.3 |
HYPR | 2023-12-22 | 8.1 | 0.8 | -1.7 | 0.2 |
HYPR | 2023-12-21 | 7.8 | 0.8 | -1.6 | 0.2 |
Hyperfine, Inc. (HYPR) Company Bio
Hyperfine, Inc. operates as a medical imaging device company. It offers Swoop system, a portable magnetic resonance imaging system. The company was founded in 2014 and is based in Guilford, Connecticut.
Latest HYPR News From Around the Web
Below are the latest news stories about HYPERFINE INC that investors may wish to consider to help them evaluate HYPR as an investment opportunity.
Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023GUILFORD, Conn., November 20, 2023--Hyperfine, Inc. announces presentations on clinical advancements at RSNA 2023 |
Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare ConferenceGUILFORD, Conn., November 16, 2023--Hyperfine, Inc. to present at the Piper Sandler 35th annual healthcare conference. |
Hyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call TranscriptHyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call Transcript November 10, 2023 Operator: Good afternoon, and welcome to Hyperfine’s Third Quarter 2023 Earnings Conference Call. Currently, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay […] |
Hyperfine, Inc. Reports Third Quarter 2023 Financial ResultsGUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 financial results and provided a business update. “We remain focused on our three strategic pillars of innovation, clinical evidence, and commercialization, all while actively managing o |
Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO PatientsGUILFORD, Conn., November 02, 2023--Observational study finds that Hyperfine, Inc. portable MR brain imaging system assists clinicians in early detection of ABI in ECMO patients |
HYPR Price Returns
1-mo | 7.21% |
3-mo | 13.33% |
6-mo | -40.20% |
1-year | -15.00% |
3-year | -88.04% |
5-year | N/A |
YTD | 6.25% |
2023 | 33.33% |
2022 | -88.41% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...